[go: up one dir, main page]

CN108601916A - In-line nasal delivery device - Google Patents

In-line nasal delivery device Download PDF

Info

Publication number
CN108601916A
CN108601916A CN201680060459.8A CN201680060459A CN108601916A CN 108601916 A CN108601916 A CN 108601916A CN 201680060459 A CN201680060459 A CN 201680060459A CN 108601916 A CN108601916 A CN 108601916A
Authority
CN
China
Prior art keywords
engaging portions
compound
dosage chamber
propellant
shell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680060459.8A
Other languages
Chinese (zh)
Other versions
CN108601916B (en
Inventor
J·D·赫克曼
C·富勒
C·科林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inbell Pharmaceutical Co
Original Assignee
Impel Neuropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impel Neuropharma Inc filed Critical Impel Neuropharma Inc
Publication of CN108601916A publication Critical patent/CN108601916A/en
Application granted granted Critical
Publication of CN108601916B publication Critical patent/CN108601916B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A delivery device for a composite comprising: a housing, a vial holding the composite, and a propellant source, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the propellant source and is directed away from the in-line nasal delivery device composite, and the outlet allows delivery of the composite.

Description

In-line arrangement nasal delivery device
The cross reference of related application
This application claims the U.S. Provisional Patent Application No.62/216 that September in 2015 is submitted on the 10th, and 789 priority should Application is by quoting whole be incorporated herein.
Background technology
Since the complicated structure of nasal cavity and the gyroscope-like for sucking air by nose guide air path, it is difficult to real Existing be by drug deposition on the olfactory region of nasal cavity.These natural structures are used for that material is prevented to be deposited on olfactory region, To the mode as protection into this access path of central nervous system (CNS).Nasal drop or spraying device are (such as Pfieffer nose sprays device (Radolfzell, Germany)) it is designed to that lower part nasal cavity is made to be saturated.It is deposited on the nasal cavity of lower part Drug is absorbed into blood flow, rather than in CNS, the advantages of eliminating for CNS deliverings using nasal cavity path.
Need a kind of more efficient method of the intranasal delivery of compound or mixture.
Invention content
It is shown and it is described be a kind of a kind of application of the device for compound intranasal delivery comprising y- combine Portion, the engaging portions y- include base portion, the engaging portions y- slave base portion diverging the first branch, the engaging portions y- slave base portion diverging second Branch, the third branch of slave base portion diverging of the engaging portions y- and the internal dose of the engaging portions y- load channel；Dosing pumps, It is connected to the first branch fluid of the engaging portions y-；Volute spring, it is associated with the second branch of the engaging portions y-；Dosage chamber, It is connected to the third branch fluid of the engaging portions y-；Nozzle, it is associated with dosage chamber；Diffuser, internally positioned dosage It loads between channel and dosage chamber；Actuator grip part surrounds the engaging portions y-；And shell, y- binding sites are in shell It is interior.
In one aspect, in-line arrangement nasal delivery device further includes propellant tank, the second affluent-dividing with the engaging portions y- Body is connected to and is kept by actuator grip part, and volute spring is located between propellant tank and the second branch of the engaging portions y-.
On the other hand, in-line arrangement nasal delivery device further includes the medicine bottle being in fluid communication with dosing pump.
It yet still another aspect, in-line arrangement nasal delivery device further includes by pump accessory of the dosing pump fixed to medicine bottle.
In another application, it is shown and it is described be that a kind of in-line arrangement nasal delivery for compound intranasal delivery fills It sets comprising shell, shell include end, actuator and dosage chamber, and end and dosage chamber are in fluid communication in shell；Position Nozzle at the distal part of end, nozzle provide the outlet for compound；And the pump being in fluid communication with dosage chamber, Pump moves to compound in dosage chamber.
In one aspect, in-line arrangement nasal delivery device further includes the propellant tank being connected to shell fluid, propellant tank It is in fluid communication with propellant valve and with dosage chamber.
On the other hand, in-line arrangement nasal delivery device further includes compound medicine bottle, is cooperated so as to by compound with pump It moves in dosage chamber.
On the other hand, in-line arrangement nasal delivery device compression pump at the time of activation, makes compound move in dosage chamber, And the actuating of propellant valve disperses propellant, pushes compound, and compound is made to pass through nozzle opening separating device.
In conjunction with any attached drawing the present invention is best understood from reference to the described in detail below of a variety of applications.Following description is It is descriptive, illustrative and exemplary of, it is not regarded as limitation by any range defined in the appended claims.
Description of the drawings
With making it be best understood from reference to described in detail below in conjunction with attached drawing, above aspect and many advantages will obtain It is understood more readily from, in attached drawing：
Fig. 1 shows the cross section of in-line arrangement nasal delivery device.
Fig. 2 shows in the cross-sectional view stood with the in-line arrangement nasal delivery device of actuation phase.Fig. 2A shows to stand When in-line arrangement nasal delivery device, Fig. 2 B show the actuating of pump, and Fig. 2 C show the actuating of propellant valve.
Fig. 3 shows the cross section of the another application of in-line arrangement nasal delivery device.
Fig. 4 shows the cross section of the diffuser of seating in the device.
Fig. 5 A show the decomposition view of unassembled dosage chamber and the engaging portions y-.
Fig. 5 B show the decomposition view of the dosage chamber and the engaging portions y- of cooperation.
Fig. 6 illustrates that the arrow of dosage and propellant flowing.
Fig. 7 shows actuator grip part and volute spring configuration.
Fig. 8 shows the side view of the cross section and optional nose cone of optional nose cone.
Specific implementation mode
In this paper commodity in use titles, it includes independently trade name product and formula that applicant, which is intended to, general compound The active pharmaceutical ingredient of object and trade name product.
It is clear in order to disclose, and not limit, detailed description is divided into following chapters and sections.
Unless otherwise defined, all technical and scientific terms used herein has and described method, equipment and multiple It is identical to close the normally understood meaning of one of the those of ordinary skill in the relevant field of object.As used herein, term below and Phrase, which has, belongs to its meaning, unless in addition clear：
"one" or " one " may imply that one or more.
In one application, compound is delivered to nasal cavity and more than nasal valve by compound by in-line arrangement nasal delivery device 1 It is deposited in nasal cavity.Deposition portion includes turbinate and/or olfactory region.The compound of delivering is liquid.Compound can be medicine Product, active pharmaceutical ingredient or pharmaceutical formulation.The compound of delivering can be dosage.
As shown in Figure 1, in-line arrangement nasal delivery device 1 includes shell 10, diffuser 20, end 35, nozzle 40, dosing chamber Room 45, actuator 50 and compound is moved to the pump 25 in dosage chamber 45.In one aspect, in-line arrangement nasal devices 1 with push away Into agent tank 5, propellant valve 15 and related to the compound medicine bottle 30 that the pump 25 for moving to compound in dosage chamber 45 cooperates Connection and cooperation.
In one aspect, diffuser 20 is glaze (frit) 21.Diffuser is used for the liquefied propellant in propellant tank 5 It is converted into gas and/or for making propellant temperature increase.
In one aspect, propellant valve 15 is dosing propellant valve 16.
In one aspect, compound is supplied in the form of the sealed vial 30 of such as glass, and medicine bottle accommodates a certain amount of liquid Body.In one aspect, medicine bottle 30 has (such as, but not limited to passes through plastics by the sealing of 32 (not shown) of movable closure member Lid, flanging metal seal and rubbery stopper (for stablize and sterilization purpose) sealing) neck 31.In one aspect, medicine bottle 30 can accommodate active pharmaceutical ingredient.When closure member 32 is removed, device 1 is engaged with medicine bottle 30, in one aspect, by with The neck 31 of medicine bottle 30 cooperates.Pump 25 moves to compound in dosage chamber 45.
Propellant tank 5 is the tank of compressed gas or liquefied propellant.Compressed gas include but is not limited to compressed air and Compress hydrocarbon.In one aspect, nitrogen or carbon dioxide.Liquefied propellant includes but is not limited to chlorofluorocarbon and hydrogen fluorine Alkane.Propellant valve 15 will be usually arranged in tank 5, it is possible thereby to control gas flowing.
End 35 includes nozzle 40.In one aspect, nozzle 40 has 41 (not shown) of multiple nozzle openings.By multiple Nozzle opening 41, compound and propellant are delivered to nasal cavity.
The actuating of propellant tank 5 is effectively cooperateed with the actuating of the pump 25 for compound medicine bottle 30.This configuration is so that multiple The actuating for closing object medicine bottle 30 causes the actuating of propellant tank 5.Fig. 2 shows devices when standing (Fig. 2A) and actuating (Fig. 2 B and 2C) 1。
As an example, the actuating of device 1 was divided into such as the next stage.Shell 10 is compressed for that propellant tank 5 is perfused.In shell When body 10 is compressed, the remains stationary in shell 10 of actuator 50, while propellant tank 5 and medicine bottle 30 are transported towards actuator 50 It is dynamic.At this point, 15 obstructed overcompression of propellant valve associated with propellant tank 5 activates.Actuator 50 acts on pump 25, compression Pump 25, and the compound from medicine bottle 30 moves in dosage chamber 45.Dosage chamber 45 is moved in most of compound After interior, actuator 50 acts on propellant valve 15, and propellant valve 15 starts to compress.The continuous pressing of actuator 50 makes Propellant is obtained to discharge from propellant tank 5.Propellant with its through being located in the nozzle opening 41 of nozzle 40 in end 35 from Opening apparatus 1 and push compound.First actuating of the setting of actuator 50 for pumping 25, then once pump 25 empties, actuator 50 It is continuous pressing for make propellant from tank 5 discharge.
In the alternate application (not shown) of device 1, device 1 does not include diffuser 20.
Fig. 3 shows the another application of device 100.Device 100 can deliver single or multiple doses from medicine bottle 30 or other containers Amount.Device 100 allows multiple dosage to be delivered from medicine bottle 30, or delivering single dosage.For example, medicine bottle 30 can be accommodated for multiple doses The volume of the compound of amount, and user can determine only to deliver single dosage from medicine bottle 30.Compound can be drug, active medicine Ingredient or pharmaceutical formulation.
Initially, medicine bottle 30 can be separately from other sections with assembled device 100.When in use, device 100 and medicine bottle 30 respectively pack taking-up from it.Before the use, medicine bottle 30 is typically to be sealed.It is close by plastic lid, metal in medicine bottle 30 In the case that sealing or plug cover, plastic lid and metal seal are pulled away from the top of medicine bottle 30, and rubbery stopper It is removed from medicine bottle 30.Medicine bottle 30 can screw in the pump accessory 180 being located at the base portion of device 100.For example, but not limiting System, medicine bottle 30 can have negative thread, negative thread that can screw in the male thread on pump accessory 180, or vice versa.Medicine bottle 30 The such as, but not limited to compound of 2-3ml (including end value) can be accommodated, includes the compound of 2-2.5ml on the other hand Object.
As shown in figure 3, device 100 includes shell 110.The component of 110 storing apparatus 100 of shell, including the engaging portions y- 120.The engaging portions y- 120 have three branches dissipated from common base.The engaging portions y- and three of them branch can be molding section Part.Fluid and gas path are established in the engaging portions y- 120 in device 100, and will meter when propellant tank 140 and device assemble Amount dosing pump 130, dosage chamber 150 and propellant tank 140 link together.
As shown in figure 3, in order to use the device 100, user will be generally oriented device 100, and wherein propellant tank 140 is assembled At the top of being located in, and medicine bottle 30 assembles and is located in bottom.It is contained in the shell 100 of device 100, optional check-valves In the reception set for the first branch that 160 (are attached to dosing and pump 130 shanks) are press-fitted into the engaging portions y- 120.Inner openings It provides from the 130 optional check-valves 160 of process of dosing pump and the engaging portions y- 120 to the fluid communication of dosage chamber 150. On one side, check-valves 160 is elastomer member, and plastic housing is mounted between dosing pumps the engaging portions 130 and y- 120 In vivo.Optional check-valves 160：(a) the dosage leakage that dosing pump 130 occurs can be passed through by, which having reduced or eliminated, (is pumping handle In the case that portion is pressed and propellant tank 140 is activated)；(b) consistency of the dosage of the delivering of device 100 is allowed to be changed It is kind；And/or compound is made not to be pushed back into dosing pump 130 along the internal dose of the engaging portions y- 120 load channel 230 It is interior.
It is oriented in operation in use, be contained in the shell 110 of device 100, towards the top of device 100, Propellant tank 140 is press-fitted into the second branch of the engaging portions y- 120, is established and is arrived agent by inner openings, by diffuser 170 Measure the gas path of chamber 150.
In this application of device 100, diffuser 170 is ring-shaped.As shown in figure 4, circular diffuser 170 is seated in In aperture on the rear end of dosage chamber 150.The overall diameter of circular diffuser 170 carries out compressed fit with dosage chamber 150. When dosage chamber 150 is installed on the engaging portions y- 120, the internal dose load for being molded into a part for the engaging portions y- 120 is logical Road 230 is cooperated in the inner openings of circular diffuser 170.The inside of the interior diameter and the engaging portions y- 120 of circular diffuser 170 Dosage loads channel 230 and is partially compressed.Circular diffuser 170 is seated in the outer wall and dosing chamber in internal dose load channel 230 Between the inner wall of room 150, recline the sealing of both these surfaces, to form the bottom of dosage chamber 150.
In one aspect, diffuser 170 is glaze 171.Diffuser 170：(a) it is arranged to the liquid in propellant tank 140 Change propellant and is converted into gas；(b) so that propellant temperature increases；(c) it is used for preventing propellant from flowing back to device 100；(d) it is used for Prevent complex logistics return device 100；And/or (e) be used for that gas is allowed to flow into dosage chamber 150, while preventing compound from leaking. Diffuser can be made of porous polymeric materials.
Device 100 is in compound, circular diffuser 170, internal dose load pipe 230, dosage chamber 150 and the engaging portions y- The relationship operated between 120 is at least shown in FIG. 6.In operation, the compound in dosage chamber 150 is loaded into using limitation Minimum access, outflow medicine bottle 30 and filling dose chamber 150, rather than load by circular diffuser 170 and enters backward The propellant delivery path of the engaging portions y- 120.In the operation of device 100, the time quantum needed for operational phase and device operation Allow circular diffuser 170 to limit complex logistics and is moved back into the engaging portions y- 120 up to needing the period, because of propellant tank 140 Start after compound load.It is appropriate during use in device 100, device 100 (including dosing pump 130 and propellant Tank 140) it is fully actuated close to one second or less than one second.Load dosage in dosage chamber 150 do not have enough time to After flow in the engaging portions y- 120.Just after dosage chamber 150 is full of, compound is discharged propellant from device 100.
In the engaging portions y- 120 on the third leg of 45 degree of angles, dosage chamber 150 is press-fitted into the engaging portions y- In 120, the flow path for gas and fluid by device is completed.In one aspect, angle be 30 degree, 35 degree, 40 degree, 45 degree, 50 degree, 55 degree, 60 degree, including end value and intermediate angle.
The engaging portions y- 120 may include matching rib (not shown), to help component to be fixed and is located in device 100 In shell 110.
Device 100 includes pump accessory 180.It pumps accessory 180 and dosing pump 130 is fixed to medicine bottle 30, and in device 100 are during use held in place two components.The one side of pump accessory 180 is that it includes keeping it in shell 110 Matching rib interior, that vertical displacement is provided and prevents rotation during medicine bottle 30 is installed.
Device 100 includes dosage chamber 150.Dosage chamber 150 receives and stores the inner tube for being pushed out the engaging portions y- 120 Compound.When propellant tank 140 is activated, the engaging portions y- 120 and dosage chamber 150 are pressurized, and propellant gas By compound discharge dosage chamber 150.As shown in Figure 5 A and 5B, dosage chamber 150 is press fit into the engaging portions y- 120.Spray Mouth 190 is mounted to the end opposite with the end that it is press-fitted into the engaging portions y- 120 of dosage chamber 150.
Nozzle 190 is mounted in the distal end of dosage chamber 150 (to be press fit into y- to be combined with dosage chamber 150 The opposite end in the end in portion 120), it is formed around the liquid-tight and gas-tight seal of overall diameter.In the activating of device 100, push away Liquid complex is emptied from dosage chamber 150 into agent, it is made to release nozzle 190.
Nozzle 190 forms small plum grape (such as the angle of 1-40 degree, including end value and the angle between it；A side Face, the angle are 5 degree, 10 degree, 15 degree, 20 degree, 25 degree, 30 degree, 35 degree) multithread deposition.Nozzle 190 and it is formed by synthesis plumage Angle promotion compound is delivered to the olfactory region of user's nasal cavity.
In this application, as shown in figure 8, device 100 may include optional nose cone 200.The exterior geometry of nose cone 200 Offer device 100 is contributed to be properly aligned with during being inserted into nose.Plane side diametrically help to recline any nostril every Film is placed, and the offer of depth stop member is properly inserted depth.Nose cone 200 is spray by the mechanical interference being attached in design Mouth 190 provides remaining.As shown in figures 3 and 8, there is the opening being aligned with nozzle 190 in nose cone 200.Nose cone 200 is not to add A part for the flow path of pressure.
Shell 110 represents the main body of device 100.The component of shell 110 including concealing device 100 and keep all components with Ensure two different " clam shells " of function.Shell 100 accommodates dosing pump 130 and pump accessory 180, actuator grip part 210, the engaging portions y- 120, propellant tank 140 and dosage chamber 150.Nose cone 200 is bonded on the exterior geometry of shell 100 On.Shell 110 is designed to facilitate group by using such as, but not limited to U.S. safe pin, buckle, column or screw or combinations thereof Dress, or be molded into the geometry.
The setting of actuator grip part 210 by user for carrying out actuated displacement.Actuator grip part 210 includes two portions Point, i.e. actuator grip part A and actuator grip part B, the circular engaging portions y- 120 are simultaneously located in shell 110.Fig. 7 shows two A finger grip notch 215, is designed into actuator grip part 210, to allow user (such as but not limited to finger In index finger and middle finger) engagement device 100.These finger grip notches 215 allow user's application to move downward, and lead to device 100 actuatings.
Compound is drawn into the engaging portions y- 120 by dosing pump 130 from medicine bottle 30.It is fixed that dosing pump 130 can be used The pump accessory 180 of system with the function in promote device 100, and allows medicine bottle 30 via thread attachment.Dosing pump 130 can To be such as, but not limited to the volume of 180 μ l, 200 μ l or 230 μ l in activating delivering.The meter being commercially available can be used Measure dosing pump 130.
In order to make the consistently delivery complexes of device 100, dosing pump 130 must delivery complexes first, then It is activated by propellant tank 140 compound is discharged.As shown in fig. 7, realizing that a kind of mode of this purpose is via positioned at propulsion Volute spring 220 between agent tank 140 and the engaging portions y- 120 causes to measure to form the required actuating power of propellant tank 140 Correct actuation sequence between dosing pump 130 and propellant tank 140.In one application, using volute spring 220, although can Using other mechanisms, this power is not limited to be generated by volute spring 220.In one aspect, volute spring 220 has close to zero Preloading, have about 25.5lbf the k values of in and the maximum load of 3.2lbf.The selection of spring or mechanism will include with Under consider：(a) make the 100 appropriate division stage of device；(b) real space in device 100；And/or (c) and related Conical Projectile The user feedback how of the hardness of spring 220 allows a variety of user's actuation means 100 always.
Volute spring 220 by in-line is mounted between propellant tank 140 and the engaging portions y- 120.Actuator grip part 210 Physically keeping propellant tank 140.User from medicine bottle 30 for example, by from actuator grip part 210 and applying directly downwards upwards Row power carrys out actuation means 100.The power is simultaneously for both actuated metered dose pump 130 and propellant tank 140.Volute spring 220 It is parallel to internal propellant tank spring to be acted on, increases the necessary power needed for actuating propellant tank 140.By selecting Conical Projectile Spring 220 is so that the necessary power of maximum needed for actuating propellant tank 140 must more than the maximum needed for fully actuated dosing pump 130 Palpus power, device 100 are arranged to start compound dosage is loaded into dosing chamber before the discharge of device 100 in propellant gas In room 150.
In 100 activating of device, dosing pump 130 is via the engaging portions y- 120 from medicine bottle at the bottom of device 100 300 extract liquid complex, load channel 230 by internal dose and enter dosage chamber 150.Internal dose loads channel 230 provide unimpeded path to be loaded into the compound before circular diffuser 170, without actually passing annular diffusion The porous material of device 170.As shown in fig. 6, small arrow represents the flowing of propellant, and big arrow represents the flowing of compound.It fills Injected current needs to be filled up completely the internal dose load that dosing pumps the engaging portions 130 and y- 120 before user carries out dosage Channel 230.Dosage cap (not shown) can cladding system 100 nose cone 200, and retain perfusion jet stream, while also providing to the user The measure visually indicated that device is poured.
In the second stage that device 100 activates, once dosage chamber 150 is filled, the release of propellant tank 140 is tied by y- The propellant that the top in conjunction portion 120 enters, it then follows Fig. 6 opens path shown in arrow.Propellant actually flows through annular diffusion The porous material of device 170, this promotes the evaporation of propellant.Propellant is first in the circular diffuser 150 being seated in device 100 Distal face (distal side closer to nozzle 190, nearside further from nozzle 190) at contact compound.As propellant continues to expand, Propellant in dosage chamber 150 forward (towards nozzle 190) push compound, make its end of dosage chamber 150 from Open nozzle 190.
Propellant tank 140 is that device 100 provides promotion energy.The shank of propellant valve is seated in the top of the engaging portions y- 120 In portion's receiver.During use, user presses down in actuator grip part 210, and the main body of propellant tank 140 is downward It pulls, activates propellant valve.The metered volume of this release liquid propellant.With propellant evaporation and expansion, compound is forced It leaves dosage chamber 150 and is left by nozzle 190.
As the example (but being not limited) of propellant, propellant tank 140 uses propulsions of the HFA134A as system Agent.It is contemplated that other propellants.What propellant tank 140 was a commercially available.
Device 100, propellant tank 140 and medicine bottle 30 can all together included or be arranged in external member.
Example and embodiment
Example 1
Following table provides a kind of application of device described herein.
Following clause describes a variety of possible embodiments for implementing features described herein.It is described herein a variety of Embodiment is there is no limit meaning, nor there must be from any given embodiment and in another embodiment Each feature.Any two or numerous embodiments can be combined, unless clearly dictating otherwise herein.As made herein With, within this document, "or" mean and/or.For example, " A or B " means that A does not have B, B not to have A or A and B.As made herein With " comprising " means to include all features enumerated, and may include the addition for other features that do not enumerate." substantially Including " mean to include that those of the feature enumerated and basic and novel features without substantially influencing cited feature are attached Add feature." comprising " only means that the feature enumerated, and excludes any feature that do not enumerate.
A kind of device for compound intranasal delivery of clause 1., including：
The engaging portions y- comprising base portion, the first branch of slave base portion diverging of the engaging portions y-, the slave base portion of the engaging portions y- are sent out The third branch of slave base portion diverging of scattered the second branch, the engaging portions y- and the internal dose of the engaging portions y- load channel；
Dosing pumps, and is connected to the first branch fluid of the engaging portions y-；
Volute spring, it is associated with the second branch of the engaging portions y-；
Dosage chamber is connected to the third branch fluid of the engaging portions y-；
Nozzle, it is associated with dosage chamber；
Diffuser, between internally positioned dosage load channel and dosage chamber；
Actuator grip part surrounds the engaging portions y-；And
Shell, y- binding sites are in shell.
Device of the clause 2. according to any one of clause 1-11 further include：
Propellant tank is connected to the second branch fluid of the engaging portions y- and is kept by actuator grip part, Conical Projectile Spring is located between propellant tank and the second branch of the engaging portions y-.
Device of the clause 3. according to any one of clause 1-11 further includes the medicine being in fluid communication with dosing pump Bottle.
Device of the clause 4. according to clause 3 further includes by pump accessory of the dosing pump fixed to medicine bottle.
Device of the clause 5. according to any one of clause 1-11 further includes between dosing pump and the engaging portions y- Associated check-valves.
Device of the clause 6. according to any one of clause 1-11 further includes the nose cone engaged with shell.
Device of the clause 7. according to clause 6 further includes the dosage cap for covering nose cone.
Device of the clause 8. according to any one of clause 1-11, wherein the third branch of the engaging portions y- is relative to y- The base portion of engaging portion is located at 45 degree of angles.
Device of the clause 9. according to any one of clause 1-11, wherein diffuser is ring-shaped.
Device of the clause 10. according to any one of clause 1-11, wherein diffuser is porous material.
Device of the clause 11. according to any one of clause 1-11, wherein diffuser forms the bottom of dosage chamber.
A kind of device for compound intranasal delivery of clause 12., described device include：
Shell, shell include end, actuator and dosage chamber, and end and dosage chamber are connected to shell fluid；
Nozzle is located at the distal part of end, and nozzle provides the outlet for compound, and nozzle includes multiple nozzles Opening；And
Pump is in fluid communication with dosage chamber, and in actuator activation, pump moves to compound in dosage chamber.
Device of the clause 13. according to any one of clause 12-15 further includes propellant tank associated with shell, Propellant tank has for the propellant valve by actuator activation, and propellant tank is in fluid communication with dosage chamber.
Device of the clause 14. according to any one of clause 12-15 further includes compound medicine bottle, associated with pump So that compound is moved to from medicine bottle in dosage chamber.
Device of the clause 15. according to any one of clause 12-15, further includes diffuser.
A kind of device for olfactory region of the compound intranasal delivery to nasal cavity of clause 16., described device include：
Shell, shell include end, actuator and dosage chamber, and end and dosage chamber are connected to shell fluid；
Nozzle is located at the distal part of end, and nozzle provides the outlet for compound, and nozzle includes multiple nozzles Opening；
Pump is in fluid communication with dosage chamber, and in actuator activation, pump moves to compound in dosage chamber；
Propellant tank, associated with shell, propellant tank has for the propellant valve by actuator activation, promotes Agent tank is in fluid communication with dosage chamber；And
Compound medicine bottle, it is associated with pump, to move in dosage chamber compound from medicine bottle, wherein in device When actuating, actuator compression pump makes compound move in dosage chamber, and the actuating of propellant valve disperses propellant, pushes away Dynamic compound so that compound passes through multiple nozzle opening separating devices.
A kind of 17. external member of clause includes device, propellant tank and medicine bottle according to any one of clause 1-16.
The present invention is not limited to the range of concrete application described herein.In fact, those of ordinary skill in the art from A variety of modifications of the present invention except being described herein are readily apparent that in upper description and attached drawing.These modifications are intended to fall within appended right and want In the range of asking.

Claims (17)

1. a kind of device for compound intranasal delivery, including：
The engaging portions y- comprising base portion, the first branch of slave base portion diverging of the engaging portions y-, the slave base portion of the engaging portions y- dissipate Second branch, the third branch of slave base portion diverging of the engaging portions y- and the internal dose of the engaging portions y- load channel；
Dosing pumps, and is connected to the first branch fluid of the engaging portions y-；
Volute spring, it is associated with the second branch of the engaging portions y-；
Dosage chamber is connected to the third branch fluid of the engaging portions y-；
Nozzle, it is associated with dosage chamber；
Diffuser, between internally positioned dosage load channel and dosage chamber；
Actuator grip part surrounds the engaging portions y-；And
Shell, y- binding sites are in shell.
2. the apparatus according to claim 1, further including：
Propellant tank is connected to the second branch fluid of the engaging portions y- and is kept by actuator grip part, volute spring position Between propellant tank and the second branch of the engaging portions y-.
3. the apparatus according to claim 1, further including the medicine bottle being in fluid communication with dosing pump.
4. device according to claim 3 further includes by pump accessory of the dosing pump fixed to medicine bottle.
5. the apparatus according to claim 1, further including the associated check-valves between dosing pump and the engaging portions y-.
6. the apparatus according to claim 1, further including the nose cone engaged with shell.
7. device according to claim 6 further includes the dosage cap for covering nose cone.
8. the apparatus according to claim 1, wherein the third branch of the engaging portions y- is located at relative to the base portion of the engaging portions y- At 45 degree of angles.
9. the apparatus according to claim 1, wherein diffuser is ring-shaped.
10. the apparatus according to claim 1, wherein diffuser is porous material.
11. the apparatus according to claim 1, wherein diffuser forms the bottom of dosage chamber.
12. a kind of external member comprising the apparatus according to claim 1, propellant tank and medicine bottle.
13. a kind of device for compound intranasal delivery, described device include：
Shell, shell include end, actuator and dosage chamber, and end and dosage chamber are in fluid communication in shell；
Nozzle is located at the distal part of end, and nozzle provides the outlet for compound, and nozzle includes that multiple nozzles are opened Mouthful；And
Pump is in fluid communication with dosage chamber, and in actuator activation, pump moves to compound in dosage chamber.
14. device according to claim 13 further includes propellant tank associated with shell, propellant tank, which has, to be used for By the propellant valve of actuator activation, propellant tank is in fluid communication with dosage chamber.
15. device according to claim 13 further includes compound medicine bottle, it is associated with pump so as to by compound from medicine Bottle moves in dosage chamber.
16. device according to claim 13 further includes diffuser.
17. a kind of device for olfactory region of the compound intranasal delivery to nasal cavity, described device include：
Shell, shell include end, actuator and dosage chamber, and end and dosage chamber are connected to shell fluid；
Nozzle is located at the distal part of end, and nozzle provides the outlet for compound, and nozzle includes that multiple nozzles are opened Mouthful；
Pump is in fluid communication with dosage chamber, and in actuator activation, pump moves to compound in dosage chamber；
Propellant tank, associated with shell, propellant tank has for the propellant valve by actuator activation, propellant tank It is in fluid communication with dosage chamber；And
Compound medicine bottle, it is associated with pump, to move in dosage chamber compound from medicine bottle, wherein being activated in device When, actuator compression pump makes compound move in dosage chamber, and the actuating of propellant valve disperses propellant, pushes multiple Close object so that compound passes through multiple nozzle opening separating devices.
CN201680060459.8A 2015-09-10 2016-09-09 In-line nasal delivery device Active CN108601916B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216789P 2015-09-10 2015-09-10
US62/216,789 2015-09-10
PCT/US2016/051169 WO2017044897A1 (en) 2015-09-10 2016-09-09 In-line nasal delivery device

Publications (2)

Publication Number Publication Date
CN108601916A true CN108601916A (en) 2018-09-28
CN108601916B CN108601916B (en) 2021-07-09

Family

ID=58240152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680060459.8A Active CN108601916B (en) 2015-09-10 2016-09-09 In-line nasal delivery device

Country Status (14)

Country Link
US (4) US11266799B2 (en)
EP (1) EP3341059B1 (en)
JP (2) JP6753927B2 (en)
KR (1) KR20180052662A (en)
CN (1) CN108601916B (en)
AU (1) AU2016321345B2 (en)
CA (1) CA2998182A1 (en)
HK (1) HK1252257A1 (en)
IL (1) IL257845B (en)
MA (1) MA42708A (en)
MX (1) MX2018002895A (en)
NZ (1) NZ741171A (en)
WO (1) WO2017044897A1 (en)
ZA (1) ZA201801543B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044897A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma Inc. In-line nasal delivery device
FR3046553B1 (en) * 2016-01-07 2018-02-16 Aptar France Sas NASAL DISTRIBUTION SET OF FLUID PRODUCT.
AU2018334334B2 (en) 2017-09-15 2024-06-13 Shin Nippon Biomedical Laboratories, Ltd. Medicine storage cartridge with nozzle, sprayer therefor, and powdered medicine dispensing device for nasal cavity
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
JP2021503988A (en) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド Intranasal device with inlet interface
CA3088942C (en) * 2018-01-05 2023-01-03 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
CA3125430A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
KR20220137033A (en) 2020-01-22 2022-10-11 실로스 테라퓨틱스, 인크. NMDA antagonists with reduced side effects
US20240261236A1 (en) 2021-05-14 2024-08-08 Seelos Therapeutics, Inc. Methods of using nmda receptor antagonists
TW202310825A (en) 2021-05-14 2023-03-16 美商西羅斯醫療公司 Reducing side effects of nmda receptor antagonists
KR20240045885A (en) 2022-09-30 2024-04-08 주식회사 이엠텍 Intranasal inhaler

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921857A (en) * 1973-11-29 1975-11-25 Ciba Geigy Corp Non-spitting liquid dispensing device
WO2003106840A2 (en) * 2002-06-13 2003-12-24 Medquest Products Inc. Low profile inlet for an implantable blood pump
WO2007081948A2 (en) * 2006-01-06 2007-07-19 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20080017190A1 (en) * 2004-12-03 2008-01-24 Aparna Anandampillai Resonating (alerting) metered dose inhaler
US20080223363A1 (en) * 1999-03-03 2008-09-18 Optinose As Nasal Delivery Devices
US20100242958A1 (en) * 2007-11-06 2010-09-30 3M Innovative Properties Company Medicinal inhalation devices and components thereof
CN201759968U (en) * 2010-09-14 2011-03-16 刘永辉 Medicine spraying device for anesthesia
CN202263268U (en) * 2011-07-08 2012-06-06 宝鸡市德尔医疗器械制造有限责任公司 Atomizing inhalator
US20130180524A1 (en) * 2010-09-02 2013-07-18 Sipnose Ltd. Nasal delivary device
CN203139302U (en) * 2013-03-19 2013-08-21 卓效医疗有限公司 Inspiratory Synchronous Nebulization Handheld Micro Nebulizer
US20140014104A1 (en) * 2011-03-03 2014-01-16 Impel Neuropharma Inc. Nasal Drug Delivery Device
US20140034051A1 (en) * 2004-02-20 2014-02-06 Pneumoflex Systems, Llc Nebulizer having horizontal venturi

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806284A (en) 1955-11-14 1958-12-23 Chi Ah Lai A new or improved nasal inhaler
US2933259A (en) 1958-03-03 1960-04-19 Jean F Raskin Nozzle head
NL297349A (en) * 1962-08-31
US3425414A (en) 1965-05-28 1969-02-04 William J La Roche Inhalant dispenser
US3704812A (en) * 1970-06-29 1972-12-05 Ciba Geigy Corp Multi-component dispenser and valve
US3741443A (en) 1970-11-19 1973-06-26 Ciba Geigy Corp Dispensing system with propellant metering valve
US3888253A (en) 1972-08-04 1975-06-10 Beecham Group Ltd Device for administration of medicines
FR2224175B1 (en) 1973-04-04 1978-04-14 Isf Spa
US3982668A (en) 1974-10-04 1976-09-28 Ciba-Geigy Corporation Aerosol dispenser for plurality of fluent materials
CH588896A5 (en) * 1973-10-31 1977-06-15 Ciba Geigy Ag
US3971377A (en) 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
US3908654A (en) 1974-08-02 1975-09-30 Rit Rech Ind Therapeut Dispensing package for a dry biological and a liquid diluent
ZA758010B (en) 1975-11-14 1977-08-31 Syntex Inc Nasal spray adapter
DE2750090A1 (en) 1976-11-19 1978-06-01 Sandoz Ag NEW FORMS OF ADMINISTRATION FOR ORGANIC COMPOUNDS
US4095596A (en) 1976-11-26 1978-06-20 Smithkline Corporation Nasal inhaler
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4187985A (en) 1978-12-08 1980-02-12 The Continental Group, Inc. Aerosol valve for barrier type packages
BR8007911A (en) 1979-12-06 1981-06-16 Glaxo Group Ltd PERFECTED INHALER
US4412573A (en) 1981-12-28 1983-11-01 Baxter Travenol Laboratories, Inc. Injection site
WO1985002346A1 (en) 1983-11-28 1985-06-06 Vortran Corporation Gas-powered nebulizer
AU3439884A (en) 1983-11-28 1985-06-13 Vortran Corp. Single inlet prepackaged inhaler
EP0194258A1 (en) 1984-09-18 1986-09-17 Vortran Corporation All purpose nebulizer
US4896832A (en) 1987-09-07 1990-01-30 Bespak Plc Dispensing apparatus for metered quantities of pressurised fluid
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
NZ250988A (en) 1990-06-14 1995-09-26 Rhone Poulenc Rorer Ltd Powder inhaler: swirling chamber with anti-static walls
DE4038049C2 (en) 1990-11-29 1994-12-01 Anschuetz & Co Gmbh Implantable infusion pump
US5331954A (en) 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
IT1249600B (en) 1991-02-21 1995-03-09 Elettro Plastica Spa NASAL DISPENSER OF SPRAYED PHARMACEUTICAL SUBSTANCES
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
IT1250691B (en) 1991-07-22 1995-04-21 Giancarlo Santus THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
BE1006872A6 (en) 1993-03-26 1995-01-10 Merkus Franciscus W H M Nasal pharmaceutical preparations with di-hydro-ergotamine (DHE)
WO1994022445A2 (en) 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
GB9311892D0 (en) 1993-06-09 1993-07-28 Glaxo Wellcome Australia Ltd Device
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5516006A (en) 1993-07-30 1996-05-14 Meshberg; Philip Nasal dispenser
US5398850A (en) 1993-08-06 1995-03-21 River Medical, Inc. Gas delivery apparatus for infusion
IT1266794B1 (en) 1993-11-09 1997-01-21 Faustino Ballini MICRONIZED SHOWER DEVICE FOR WASHING THE NASAL AND NEIGHBORING CAVITIES
DE69523301T2 (en) 1994-05-13 2002-07-04 Aradigm Corp., Hayward A NARCOTIC AEROSOL FORMULATION
US5435282A (en) 1994-05-19 1995-07-25 Habley Medical Technology Corporation Nebulizer
JP3372105B2 (en) 1994-05-26 2003-01-27 株式会社日立ユニシアオートモティブ Inhalation type dispenser
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
DE19518580A1 (en) 1995-05-20 1996-11-21 Thomas Ossinger Electrically heated dip soldering crucible
JPH08322934A (en) 1995-05-29 1996-12-10 Unisia Jecs Corp Dosing device for nasal cavity
DE19523516C1 (en) 1995-06-30 1996-10-31 Asta Medica Ag Inhaler for administering medication from blister packs
US5823183A (en) 1995-08-02 1998-10-20 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
GB9516984D0 (en) 1995-08-18 1995-10-18 Pharmasol Ltd Spray applicator
IE77523B1 (en) 1995-09-11 1997-12-17 Elan Med Tech Medicament delivery device
US5711488A (en) 1995-10-13 1998-01-27 The Procter & Gamble Company High pressure swirl atomizer
US6678553B2 (en) 1995-11-21 2004-01-13 Intraabrain International Nv Device for enhanced delivery of biologically active substances and compounds in an organism
US5797390A (en) 1996-03-06 1998-08-25 Mcsoley; Thomas E. Nasal inhaler having a directed spray pattern
AUPN976496A0 (en) 1996-05-10 1996-05-30 Glaxo Wellcome Australia Ltd Unit dose dispensing device
US6595202B2 (en) 1996-05-13 2003-07-22 Universidad De Sevilla Device and method for creating aerosols for drug delivery
DE19622124A1 (en) 1996-06-01 1997-12-04 Alfred Von Schuckmann Device for applying liquids
US6158676A (en) 1996-06-21 2000-12-12 Hughes Technology Group, L.L.C. Micro-atomizing device
US5906198A (en) 1996-07-16 1999-05-25 Flickinger; William J. Nasal nebulizer
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6410046B1 (en) 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
DE19704849B4 (en) 1997-02-08 2011-02-17 Ing. Erich Pfeiffer Gmbh Discharge device for media
IS4516A (en) 1997-07-01 1999-01-02 Gizurarson Sveinbjörn New pharmaceutical form
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
GB9719775D0 (en) 1997-09-18 1997-11-19 Glaxo Group Ltd Device
US5954696A (en) 1997-12-15 1999-09-21 B. Braun Medical, Inc. Pressure infusion pump
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6113078A (en) 1998-03-18 2000-09-05 Lytesyde, Llc Fluid processing method
US6062213A (en) 1998-06-16 2000-05-16 Fuisz Technologies Ltd. Single unit dose inhalation therapy device
WO2000006121A1 (en) 1998-07-24 2000-02-10 Jago Research Ag Medicinal aerosol formulations
FR2782024B1 (en) 1998-08-04 2000-10-13 Valois Sa DISPENSING HEAD AND DEVICE FOR DISPENSING A FLUID PRODUCT COMPRISING SUCH A HEAD
GB2345010B (en) 1998-12-17 2002-12-31 Electrosols Ltd A delivery device
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
WO2000044432A1 (en) 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
EP3124067A3 (en) 1999-03-03 2017-05-24 Optinose AS Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
WO2000054887A1 (en) 1999-03-17 2000-09-21 Emsar, Inc. Apparatus and method for dispensing a medicinal spray
EE200100500A (en) 1999-03-26 2003-02-17 Pozen Inc. High Power Dihydroergotamine Compositions
DE19944209A1 (en) 1999-09-15 2001-03-22 Pfeiffer Erich Gmbh & Co Kg Dispenser for possibly atomizing the discharge of a medium, in particular a liquid, from a container
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
ES2214204T3 (en) 1999-10-14 2004-09-16 Becton, Dickinson And Company NASAL ADMINISTRATION DEVICE INCLUDING A SPRAY NOZZLE.
US6367471B1 (en) 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US6810872B1 (en) 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US6302101B1 (en) 1999-12-14 2001-10-16 Daniel Py System and method for application of medicament into the nasal passage
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6644305B2 (en) 2000-04-14 2003-11-11 Trudell Medical International Nasal inhaler
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
IT1317998B1 (en) 2000-06-26 2003-07-21 Medical Internat Licensing N V DISPENSING VALVE FOR NASAL SPRAY.
IT1318646B1 (en) 2000-07-26 2003-08-27 Medical Internat Licensing N V NOZZLE PR ADMINISTRATIONS AND NASAL WASHES.
EP2255806A3 (en) 2000-07-31 2011-06-29 Nycomed Danmark ApS Fentanyl composition for nasal administration
CA2359813C (en) 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
US6644309B2 (en) 2001-01-12 2003-11-11 Becton, Dickinson And Company Medicament respiratory delivery device and method
GB0109002D0 (en) 2001-04-10 2001-05-30 Glaxo Group Ltd Dispenser
GB0109001D0 (en) 2001-04-10 2001-05-30 Glaxo Group Ltd Dispenser
JP2005503425A (en) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US20030198669A1 (en) 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
US7231919B2 (en) 2001-09-28 2007-06-19 Kurve Technology, Inc. Particle dispersion device for nasal delivery
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
GB2380410B (en) 2001-10-05 2003-11-19 Alchemy Healthcare Ltd Apparatus for the nasal or oral delivery of a medicament
US7021561B2 (en) 2001-12-18 2006-04-04 Becton, Dickinson And Company Spray device and method
GB0204829D0 (en) 2002-03-01 2002-04-17 Glaxo Group Ltd A fluid dispensing device
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
CA2485217C (en) 2002-05-06 2012-05-01 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
AU2003249623A1 (en) 2002-05-09 2003-12-12 Kurve Technology, Inc. Particle dispersion chamber for nasal nebulizer
US7220457B2 (en) 2002-06-06 2007-05-22 Anderson Steven R Air atomizing assembly and method and system of applying an air atomized material
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
FR2852928B1 (en) * 2003-03-24 2006-02-24 Airlessystems FLUID PRODUCT DISPENSER.
US20060147389A1 (en) 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0309354D0 (en) 2003-04-24 2003-06-04 Glaxo Group Ltd Nozzle for a nasal inhaler
DE10321902A1 (en) 2003-05-06 2004-12-09 Ing. Erich Pfeiffer Gmbh Discharge device for at least one medium
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
WO2005023335A2 (en) 2003-09-05 2005-03-17 Kurve Technology, Inc. Integrated nebulizer and particle dispersing chamber for delivery of medicament
WO2005025506A2 (en) 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
GB0322284D0 (en) 2003-09-23 2003-10-22 Glaxo Group Ltd Medicament dispenser
WO2006039631A2 (en) 2004-09-30 2006-04-13 Centocor, Inc. Methods and compositions for treating renal cell carcinoma related pathologies
US7832394B2 (en) 2004-12-22 2010-11-16 Schechter Alan M Apparatus for dispensing pressurized contents
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
ATE440117T1 (en) 2005-04-01 2009-09-15 Intezyne Technologies Inc POLYMER MICELLES FOR MEDICINAL DELIVERY
GB0515592D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Nozzle for a nasal inhaler
US20070074722A1 (en) 2005-09-21 2007-04-05 Kurve Technology, Inc. Medicament delivery control, monitoring, and reporting system and method
CN101466397A (en) 2005-11-11 2009-06-24 奥罗根公司 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin
JP2009517184A (en) 2005-11-29 2009-04-30 アルザ・コーポレーシヨン Nasal delivery device for delivering substances to olfactory sites
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
WO2007093784A1 (en) 2006-02-14 2007-08-23 Optinose As Delivery device and method
GB0604444D0 (en) 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
US7841338B2 (en) 2006-04-13 2010-11-30 Boehringer Ingelheim International Gmbh Dispensing device
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
EP2106268B1 (en) 2006-08-30 2018-12-12 Kurve Technology, Inc. Aerosol generating and delivery device
FR2908753B1 (en) 2006-11-16 2011-11-11 Becton Dickinson France DEVICE FOR AUTOMATICALLY DELIVERING SUCCESSIVE PRODUCT DOSES
WO2008067254A2 (en) 2006-11-27 2008-06-05 Abbott Respiratory Llc Nasal drug delivery device and method
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
WO2008122018A1 (en) 2007-04-02 2008-10-09 Abbott Respiratory Llc Breath actuated nasal pump
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008154337A1 (en) 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
JP2011511674A (en) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン Circumferential aerosol device
CA2715302A1 (en) 2008-02-15 2009-08-20 Timothy Sean Immel Aerosol therapy device with high frequency delivery
US8517026B2 (en) 2008-02-25 2013-08-27 Adva Beck Amon Nasal inserts
US7875001B2 (en) * 2008-02-25 2011-01-25 Americo Michael Minotti Multi medication nasal spray device and method
NO329804B1 (en) 2009-02-09 2010-12-20 Fmc Kongsberg Subsea As Link for use in a riser, riser with such a link and method for increasing the operating window of a riser
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8839790B2 (en) 2009-07-29 2014-09-23 Adva Beck Arnon Nasal inserts
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US8408427B2 (en) 2009-09-07 2013-04-02 Mk International Pty Ltd Single dose nasal spray pump
US8925544B2 (en) 2009-12-08 2015-01-06 Medinvent, Llc Portable nebulizer device
US9757528B2 (en) 2010-08-23 2017-09-12 Darren Rubin Nebulizer having different negative pressure threshold settings
CA2820554A1 (en) 2010-11-29 2012-06-07 Sanofi-Aventis Deutschland Gmbh Medicated module for an inhaler
JP6645735B2 (en) * 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド Nose delivery nozzle
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
DE102012201178B3 (en) 2012-01-27 2013-02-14 Aptar Radolfzell Gmbh Nozzle unit and dispenser with such
US20140056990A1 (en) 2012-08-24 2014-02-27 Vr1, Inc. Composition for the treatment of migraine headaches and methods thereof
DE102013100473A1 (en) 2013-01-17 2014-07-17 Seho Systemtechnik Gmbh Method and device for cleaning a soldering nozzle
JP2016520378A (en) * 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド Medical unit dose container
US20160228433A1 (en) 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
US9603905B2 (en) 2014-03-13 2017-03-28 The Research Foundation For Mental Hygiene, Inc Intranasal insulin administration for the minimization of anesthesia-induced memory loss
WO2017044897A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma Inc. In-line nasal delivery device
FR3046553B1 (en) * 2016-01-07 2018-02-16 Aptar France Sas NASAL DISTRIBUTION SET OF FLUID PRODUCT.
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
US11000068B2 (en) * 2017-06-20 2021-05-11 Cascadia Technologies, LLC Aerosol inhalant producing device with measurable dose and/or other features
RU2019143750A (en) 2017-07-02 2021-08-03 Др. Редди'С Лабораториз Лтд. Dihydroergotamine nasal dosage forms
CA3088942C (en) 2018-01-05 2023-01-03 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921857A (en) * 1973-11-29 1975-11-25 Ciba Geigy Corp Non-spitting liquid dispensing device
US20080223363A1 (en) * 1999-03-03 2008-09-18 Optinose As Nasal Delivery Devices
WO2003106840A2 (en) * 2002-06-13 2003-12-24 Medquest Products Inc. Low profile inlet for an implantable blood pump
US20140034051A1 (en) * 2004-02-20 2014-02-06 Pneumoflex Systems, Llc Nebulizer having horizontal venturi
US20080017190A1 (en) * 2004-12-03 2008-01-24 Aparna Anandampillai Resonating (alerting) metered dose inhaler
WO2007081948A2 (en) * 2006-01-06 2007-07-19 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20100242958A1 (en) * 2007-11-06 2010-09-30 3M Innovative Properties Company Medicinal inhalation devices and components thereof
US20130180524A1 (en) * 2010-09-02 2013-07-18 Sipnose Ltd. Nasal delivary device
CN201759968U (en) * 2010-09-14 2011-03-16 刘永辉 Medicine spraying device for anesthesia
US20140014104A1 (en) * 2011-03-03 2014-01-16 Impel Neuropharma Inc. Nasal Drug Delivery Device
CN202263268U (en) * 2011-07-08 2012-06-06 宝鸡市德尔医疗器械制造有限责任公司 Atomizing inhalator
CN203139302U (en) * 2013-03-19 2013-08-21 卓效医疗有限公司 Inspiratory Synchronous Nebulization Handheld Micro Nebulizer

Also Published As

Publication number Publication date
MX2018002895A (en) 2018-07-06
EP3341059B1 (en) 2022-03-02
AU2016321345A1 (en) 2018-04-19
JP6753927B2 (en) 2020-09-09
KR20180052662A (en) 2018-05-18
US20240115819A1 (en) 2024-04-11
ZA201801543B (en) 2022-08-31
EP3341059A4 (en) 2019-05-08
AU2016321345B2 (en) 2020-12-10
IL257845A (en) 2018-04-30
JP7001777B2 (en) 2022-02-10
US20230095719A1 (en) 2023-03-30
NZ741171A (en) 2022-01-28
WO2017044897A1 (en) 2017-03-16
HK1252257A1 (en) 2019-05-24
MA42708A (en) 2018-07-04
IL257845B (en) 2022-07-01
US20180256836A1 (en) 2018-09-13
EP3341059A1 (en) 2018-07-04
JP2020185475A (en) 2020-11-19
US20230241334A1 (en) 2023-08-03
CA2998182A1 (en) 2017-03-16
CN108601916B (en) 2021-07-09
JP2018527099A (en) 2018-09-20
US11266799B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
CN108601916A (en) In-line nasal delivery device
CN104379452B (en) Improvements in or relating to dispensing valves
US9050428B2 (en) Device, cartridge and method for dispensing a liquid
US9364841B2 (en) Cartridge system
EP3615111B1 (en) Inhalation device
JP2612865B2 (en) valve
FI89698B (en) DOSERINGSAPPARAT FOER TRYCKBEHAOLLARE
US9254954B2 (en) Metering valve
WO2010094305A1 (en) Device, cartridge and method for dispensing a liquid
JP2017521195A (en) Drug delivery device
RU2017105845A (en) DEVICE FOR NASAL DELIVERY OF MEDICINES
JP2002505981A (en) Containment container, method of filling the containment container, and device for administering the fluid product stored in the containment container
EP3501582A1 (en) Nebulizer and cartridge
US20120000931A1 (en) Multiple-metered self-cleaning dispenser
US20240382701A1 (en) Inhalation device system with a counting and blocking assembly
US2872923A (en) Means for administering pressurized medicaments, gases, combinations thereof and liquids into body cavities
US7597098B2 (en) Inhaler valve mechanism
US11731148B2 (en) Apparatus and spray applicator
RU2807165C2 (en) Inhalation device and its use
JP3488717B2 (en) Miniaturized structure device for generating high pressure in atomized fluid.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Washington State

Patentee after: Inbell pharmaceutical Co.

Address before: Washington State

Patentee before: IMPEL NEUROPHARMA Inc.

CP01 Change in the name or title of a patent holder